ReviewFrontiers in immunology2026
Ferroptosis in metabolic dysfunction-associated steatotic liver disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread chronic liver disease that can progress from steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Its pathogenesis involves lipotoxicity, iron metabolism disorders, and oxidative stress-the same three processes that underlie ferroptosis, an iron-dependent form of regulated cell death mediated by the peroxidation of membrane phospholipids. However, the question of whether ferroptosis is a universal mechanism underlying the progression of MASLD as a whole or a hallmark of a distinct subgroup of patients remains unresolved. Furthermore, no ferroptosis-targeted strategy has yet been tested in a biomarker-selected population. This review addresses precisely this gap. Clinical, transcriptomic, and experimental data allow us to conceptualize hepatic ferroptosis as four interacting molecular modules: expansion of the labile pool of ferrous iron, enrichment of membranes with oxidizable polyunsaturated phospholipids, enzymatic and non-enzymatic lipid peroxidation, and failure of antioxidant defense. An imbalance in these modules leads to the accumulation of phospholipid hydroperoxides, disruption of membrane integrity, and immunogenic hepatocyte death with the release of signals that promote inflammation and fibrogenesis. At the same time, ferroptosis exhibits pronounced cellular and contextual specificity. It exerts a damaging effect on hepatocytes and sinusoidal endothelial cells, enhances inflammation in macrophages, but exerts an antifibrotic effect in activated stellate cells and immunosuppressive effects in lymphocytes. In this regard, known anti-ferroptotic strategies (iron chelation, inhibition of long-chain acyl-coenzyme A (CoA) synthase 4 (ACSL4)-dependent incorporation of polyunsaturated fatty acids, use of lipid radical scavengers and vitamin E, and activation of protective antioxidant programs) retain their diagnostic and therapeutic potential only within the framework of a molecularly and cell-stratified approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.